254 related articles for article (PubMed ID: 9422034)
1. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
2. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
3. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
4. Long-term results following 131I treatment for Graves' disease in Hong Kong Chinese--discriminant factors predicting hypothyroidism.
Kung AW; Pun KK; Lam KS; Choi P; Wang C; Yeung RT
Q J Med; 1990 Sep; 76(281):961-7. PubMed ID: 2236479
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules.
Nygaard B; Hegedüs L; Nielsen KG; Ulriksen P; Hansen JM
Clin Endocrinol (Oxf); 1999 Feb; 50(2):197-202. PubMed ID: 10396362
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
8. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
[TBL] [Abstract][Full Text] [Related]
10. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
Uy HL; Reasner CA; Samuels MH
Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
[TBL] [Abstract][Full Text] [Related]
11. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
12. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
14. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine treatment of multinodular non-toxic goitre.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Søe-Jensen P; Hansen JM
BMJ; 1993 Oct; 307(6908):828-32. PubMed ID: 8401123
[TBL] [Abstract][Full Text] [Related]
16. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
[TBL] [Abstract][Full Text] [Related]
17. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
Regalbuto C; Marturano I; Condorelli A; Latina A; Pezzino V
J Endocrinol Invest; 2009 Feb; 32(2):134-8. PubMed ID: 19411811
[TBL] [Abstract][Full Text] [Related]
18. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre.
Le Moli R; Wesche MF; Tiel-Van Buul MM; Wiersinga WM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):783-9. PubMed ID: 10468951
[TBL] [Abstract][Full Text] [Related]
19. Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism.
Gómez JM; Gómez N; Amat M; Biondo S; Rafecas A; Jaurrieta E; Soler J
Ann Endocrinol (Paris); 2000 Sep; 61(3):184-91. PubMed ID: 10970941
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
